Studying Colorectal Cancer Over Time to Guide Future Research
An observational study collecting tumor and patient samples and data from adults with colorectal cancer.
Plain-language title generated from the registry record
Registry title: ALFAOMEGA Master Observational Trial
Key facts
- Where
- Barcelona and Valencia, SpainSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who have colorectal cancer, or a strong suspicion of it, and who can give tumor tissue samples.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Colorectal cancer already diagnosed, or strongly suspected from clinical and radiological findings. ECOG performance status below 2.
- Biomarker or test result
- For people already diagnosed: stored tumor tissue (FFPE blocks), or at least 10 slides (preferably 20). Blocks are preferred.
Main reasons for not taking part
- Any other current cancer, or a cancer diagnosed or relapsed in the past 5 years (a few skin and in situ cancers are allowed)
- Cannot follow the study plan for psychological, social or geographical reasons
- Known HIV, hepatitis B, hepatitis C or syphilis infection
Read by machine on 12 November 2026.
Where in Spain
- Hospital de Sant Joan Despí - Moises BroggiBarcelona, SpainContact: Cristina Vivas, MDTaking people
- Hospital del Mar - Parc de Salut MarBarcelona, SpainContact: Clara Montagut, MDTaking people
- Hospital Moises BroggiBarcelona, SpainContact: Cristina Santos (principal investigator)Taking people
- Vall d'Hebron Institute of Oncology (VHIO)Barcelona, SpainContact: Josep Tabernero, MDTaking people
- INCLIVA - Instituto de Investigatión SanitariaValencia, SpainContact: Andrés Cervantes, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- IFOM ETS - The AIRC Institute of Molecular Oncology
- Trial code
- NCT04120935
- Record updated
- 24 August 2025
- Original description
AlfaOmega has been designed to streamline the study of the co-evolutionary landscape between tumor and host cells in a cohort of CRC patients, with the aim of understanding how their outcomes can be significantly improved (e.g. reduction of their chance of recurrence and survival improval). This clinical resource for integrative clinical data and sample collection will allow the molecular story-telling of CRC metastatic spread along time and space and the selection of appropriate patients for experimentally-driven trials.Read full original descriptionShow less
A Master Protocol Empowering Precision Research in Colorectal Cancer
AlfaOmega has been designed to streamline the study of the co-evolutionary landscape between tumor and host cells in a cohort of CRC patients, with the aim of understanding how their outcomes can be significantly improved (e.g. reduction of their chance of recurrence and survival improval). This clinical resource for integrative clinical data and sample collection will allow the molecular story-telling of CRC metastatic spread along time and space and the selection of appropriate patients for experimentally-driven trials.
Inclusion: TIER1 written Informed consent; Patients ≥18 years of age; Previous diagnosis of colorectal cancer, or a strong suspicion of CRC based on clinical and radiological findings; In patients with previous diagnosis of CRC availability of diagnostic Formalin-Fixed, Paraffin Embedded (FFPE) blocks (surgical resection and/or tumor biopsies), or at least 10 slides (preferably 20). FFPE tissue blocks are always preferred to slides; ECOG Performance status < 2.
Exclusion: Any other current malignancy or malignancy diagnosed or relapsed within the past 5 years (other than non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer); Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or syphilis infection; Patient unable to comply with the study protocol owing to psychological, social or geographical reasons.